In Section C, members will receive ABBV-744 and oral navitoclax. In Phase D, individuals will obtain ABBV-744 and ruxolitinib. Participants will acquire treatment until eventually ailment progression or even the members are unable to tolerate the study drugs. Possible new ways for that prognosis and treatment of AML. (A) The https://abbv-744drugdevelopmentpr91356.popup-blog.com/31271467/considerations-to-know-about-abbv-744-brd4-inhibitor-cancer-therapy-efficacy